,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,500 River Ridge Drive,Norwood,MA,02062,United States,617 963 0100,617 663 6085,https://www.corbuspharma.com,Biotechnology,Healthcare,"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",33,"{'maxAge': 1, 'name': 'Dr. Yuval  Cohen Ph.D.', 'age': 47, 'title': 'CEO & Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 890669, 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,9,4,7,1693526400,1672444800,86400,2,6.93,6.78,6.6301,7.02,6.93,6.78,6.6301,7.02,0.0,2.285961,-0.13323212,19431,19431,13333,11210,11210,6.51,6.99,800,900,31054234,2.11,13.17,6.92788,6.422645,0.0,0.0,USD,18207536,0.0,4411252,4423680,75383,89829,1690761600,1693440000,0.017,0.00312,0.17762,7.01,0.0171,2.153,3.2605665,1672444800,1703980800,1688083200,-46189424,-11.34,-52.69,-0.416,NCM,EQUITY,CRBP,CRBP,Corbus Pharmaceuticals Holdings,"Corbus Pharmaceuticals Holdings, Inc.",1414416600,America/New_York,EDT,-14400000,7.02,120.0,22.0,71.0,71.0,2.0,buy,2,36565904,8.266,-43748888,23719188,2.232,2.336,249.136,-0.44185,-1.5660001,-16136826,-21982424,-37615268,0.0,0.0,0.0,USD,
1,500 River Ridge Drive,Norwood,MA,02062,United States,617 963 0100,617 663 6085,https://www.corbuspharma.com,Biotechnology,Healthcare,"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",33,"{'maxAge': 1, 'name': 'Mr. Sean F. Moran CPA, M.B.A., CPA, MBA', 'age': 64, 'title': 'Chief Financial Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 579053, 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,9,4,7,1693526400,1672444800,86400,2,6.93,6.78,6.6301,7.02,6.93,6.78,6.6301,7.02,0.0,2.285961,-0.13323212,19431,19431,13333,11210,11210,6.51,6.99,800,900,31054234,2.11,13.17,6.92788,6.422645,0.0,0.0,USD,18207536,0.0,4411252,4423680,75383,89829,1690761600,1693440000,0.017,0.00312,0.17762,7.01,0.0171,2.153,3.2605665,1672444800,1703980800,1688083200,-46189424,-11.34,-52.69,-0.416,NCM,EQUITY,CRBP,CRBP,Corbus Pharmaceuticals Holdings,"Corbus Pharmaceuticals Holdings, Inc.",1414416600,America/New_York,EDT,-14400000,7.02,120.0,22.0,71.0,71.0,2.0,buy,2,36565904,8.266,-43748888,23719188,2.232,2.336,249.136,-0.44185,-1.5660001,-16136826,-21982424,-37615268,0.0,0.0,0.0,USD,
2,500 River Ridge Drive,Norwood,MA,02062,United States,617 963 0100,617 663 6085,https://www.corbuspharma.com,Biotechnology,Healthcare,"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",33,"{'maxAge': 1, 'name': 'Dr. Rachael  Brake Ph.D.', 'age': 50, 'title': 'Chief Scientific Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 552222, 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,9,4,7,1693526400,1672444800,86400,2,6.93,6.78,6.6301,7.02,6.93,6.78,6.6301,7.02,0.0,2.285961,-0.13323212,19431,19431,13333,11210,11210,6.51,6.99,800,900,31054234,2.11,13.17,6.92788,6.422645,0.0,0.0,USD,18207536,0.0,4411252,4423680,75383,89829,1690761600,1693440000,0.017,0.00312,0.17762,7.01,0.0171,2.153,3.2605665,1672444800,1703980800,1688083200,-46189424,-11.34,-52.69,-0.416,NCM,EQUITY,CRBP,CRBP,Corbus Pharmaceuticals Holdings,"Corbus Pharmaceuticals Holdings, Inc.",1414416600,America/New_York,EDT,-14400000,7.02,120.0,22.0,71.0,71.0,2.0,buy,2,36565904,8.266,-43748888,23719188,2.232,2.336,249.136,-0.44185,-1.5660001,-16136826,-21982424,-37615268,0.0,0.0,0.0,USD,
3,500 River Ridge Drive,Norwood,MA,02062,United States,617 963 0100,617 663 6085,https://www.corbuspharma.com,Biotechnology,Healthcare,"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",33,"{'maxAge': 1, 'name': 'Ted  Jenkins', 'title': 'Sr. Director of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,9,4,7,1693526400,1672444800,86400,2,6.93,6.78,6.6301,7.02,6.93,6.78,6.6301,7.02,0.0,2.285961,-0.13323212,19431,19431,13333,11210,11210,6.51,6.99,800,900,31054234,2.11,13.17,6.92788,6.422645,0.0,0.0,USD,18207536,0.0,4411252,4423680,75383,89829,1690761600,1693440000,0.017,0.00312,0.17762,7.01,0.0171,2.153,3.2605665,1672444800,1703980800,1688083200,-46189424,-11.34,-52.69,-0.416,NCM,EQUITY,CRBP,CRBP,Corbus Pharmaceuticals Holdings,"Corbus Pharmaceuticals Holdings, Inc.",1414416600,America/New_York,EDT,-14400000,7.02,120.0,22.0,71.0,71.0,2.0,buy,2,36565904,8.266,-43748888,23719188,2.232,2.336,249.136,-0.44185,-1.5660001,-16136826,-21982424,-37615268,0.0,0.0,0.0,USD,
4,500 River Ridge Drive,Norwood,MA,02062,United States,617 963 0100,617 663 6085,https://www.corbuspharma.com,Biotechnology,Healthcare,"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",33,"{'maxAge': 1, 'name': 'Ms. Lindsey  Smith', 'title': 'Head of Corp. Communications & Patient Advocacy', 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,9,4,7,1693526400,1672444800,86400,2,6.93,6.78,6.6301,7.02,6.93,6.78,6.6301,7.02,0.0,2.285961,-0.13323212,19431,19431,13333,11210,11210,6.51,6.99,800,900,31054234,2.11,13.17,6.92788,6.422645,0.0,0.0,USD,18207536,0.0,4411252,4423680,75383,89829,1690761600,1693440000,0.017,0.00312,0.17762,7.01,0.0171,2.153,3.2605665,1672444800,1703980800,1688083200,-46189424,-11.34,-52.69,-0.416,NCM,EQUITY,CRBP,CRBP,Corbus Pharmaceuticals Holdings,"Corbus Pharmaceuticals Holdings, Inc.",1414416600,America/New_York,EDT,-14400000,7.02,120.0,22.0,71.0,71.0,2.0,buy,2,36565904,8.266,-43748888,23719188,2.232,2.336,249.136,-0.44185,-1.5660001,-16136826,-21982424,-37615268,0.0,0.0,0.0,USD,
5,500 River Ridge Drive,Norwood,MA,02062,United States,617 963 0100,617 663 6085,https://www.corbuspharma.com,Biotechnology,Healthcare,"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",33,"{'maxAge': 1, 'name': 'Ms. Christina  Bertsch', 'title': 'Head of HR', 'exercisedValue': 0, 'unexercisedValue': 0}",9,4,9,4,7,1693526400,1672444800,86400,2,6.93,6.78,6.6301,7.02,6.93,6.78,6.6301,7.02,0.0,2.285961,-0.13323212,19431,19431,13333,11210,11210,6.51,6.99,800,900,31054234,2.11,13.17,6.92788,6.422645,0.0,0.0,USD,18207536,0.0,4411252,4423680,75383,89829,1690761600,1693440000,0.017,0.00312,0.17762,7.01,0.0171,2.153,3.2605665,1672444800,1703980800,1688083200,-46189424,-11.34,-52.69,-0.416,NCM,EQUITY,CRBP,CRBP,Corbus Pharmaceuticals Holdings,"Corbus Pharmaceuticals Holdings, Inc.",1414416600,America/New_York,EDT,-14400000,7.02,120.0,22.0,71.0,71.0,2.0,buy,2,36565904,8.266,-43748888,23719188,2.232,2.336,249.136,-0.44185,-1.5660001,-16136826,-21982424,-37615268,0.0,0.0,0.0,USD,
